TP53 and cancer: A Phase 1 trial (NCT02432963, Table 2) evaluating an MVA vaccine targeting mutated TP53 in combination with pembrolizumab is ongoing to identify its safety and tolerability in patients with refractory TP53 overexpressing cancer including HNSCC.